Recap: Hologic Q2 Earnings

Shares of Hologic HOLX fell in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 354.39% year over year to $2.59, which missed the estimate of $2.61.

Revenue of $1,538,000,000 higher by 103.41% from the same period last year, which missed the estimate of $1,540,000,000.

Looking Ahead

Q3 EPS expected to be between $1.00 and $1.15.

Q3 revenue expected between $1,000,000,000 and $1,070,000,000.

Conference Call Details

Date: Apr 28, 2021

Time: 04:30 PM

ET Webcast URL: https://events.globalmeet.com/Public/ClickToJoin/ZW5jPUdoMTlUeDlHZHhoVTB0TFNOUWNrK2RzaHl1NW5jVGVodEtGUTJ0WFZJNjRqaDM0NkNzNlZCZz09

Technicals

52-week high: $85.00

52-week low: $47.51

Price action over last quarter: down 12.77%

Company Overview

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!